Abstract Library

#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients

Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kjaer A

Authors: Binderup T, Johnbeck C, Loft A, Berthelsen A, Federspiel B,

Keywords: PET, PET/CT, imaging, survival,

#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,

Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,